Firstcall is bullish on Jenburkt Pharma and has recommended buy rating on the stock with a target price of Rs 520 in its research report dated January 4, 2016.
Firstcall's research report on Jenburkt Pharma
Shri Nandlal Mulji Bhuta laid the foundation of Jenburkt Pharmaceuticals Ltd. way back in the twentieth century, even before the word 'entrepreneurship' could be coined, for several group of companies and philanthropic work. Through constantly disrupting the balance of competition, efficient use of resources and capital, taking measured risks, channeling processes and delivering excellence in life sciences, today Jenburkt is respected and commended both, nationally and internationally. With a clear purpose and process in place, Jenburkt is fast growing in the field of healthcare and pharmaceuticals. It is engaged in manufacturing and marketing of specialty and high quality pharmaceutical formulations and healthcare products. A strong belief that an advancement in science promises hope, health and happiness is what drives the people of Jenburkt to commit and perform. Strong infrastructure, a well-diversified portfolio of business investments and a strong presence in major therapeutic areas have helped them stay on course. Jenburkt brings good health through quality products that include prescription and over-the-counter drugs. Company’s prescription medicines span across various therapeutic areas such as anti-arthritic, antimalarials, anti-osteoporotic, antibiotics, antidiabetics and anti-inflammatory drugs and more.
We expect that the company surplus scenario is likely to continue for the next three years, will keep its growth story in the coming quarters also. We recommend ‘BUY’ in this particular scrip with a target price of Rs. 520.00 for Medium to Long term investment.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.